Edition:
United States

Johnson & Johnson (JNJ)

JNJ on New York Consolidated

121.70USD
23 Feb 2017
Change (% chg)

$2.18 (+1.82%)
Prev Close
$119.52
Open
$119.52
Day's High
$121.90
Day's Low
$119.48
Volume
9,980,945
Avg. Vol
7,250,269
52-wk High
$126.07
52-wk Low
$102.97

JNJ

Chart for JNJ

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company's segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care,... (more)

Overall

Beta: 0.80
Market Cap(Mil.): $331,088.69
Shares Outstanding(Mil.): 2,720.53
Dividend: 0.80
Yield (%): 2.63

Financials

  JNJ Industry Sector
P/E (TTM): 20.50 28.90 29.71
EPS (TTM): 5.94 -- --
ROI: -- 13.43 12.94
ROE: -- 14.33 14.09

Genmab and J&J's cancer drug set for blockbuster sales this year

COPENHAGEN Danish biotech drugmaker Genmab expects sales of Darzalex, used to fight cancer in bone marrow, to surpass $1 billion this year to become a blockbuster drug, the company said on Wednesday.

Feb 22 2017

UPDATE 1-Genmab and J&J's cancer drug set for blockbuster sales this year

COPENHAGEN, Feb 22 Danish biotech drugmaker Genmab expects sales of Darzalex, used to fight cancer in bone marrow, to surpass $1 billion this year to become a blockbuster drug, the company said on Wednesday.

Feb 22 2017

CORRECTED-Genmab and J&J's cancer drug set for blockbuster sales this year

COPENHAGEN, Feb 22 Danish biotech drugmaker Genmab expects sales of Darzalex, used to fight cancer in bone marrow, to surpass $1 billion this year to become a blockbuster drug, the company said on Wednesday.

Feb 22 2017

Genmab's Darzalex could achieve peak annual sales of $9 bln -CEO

COPENHAGEN, Feb 22 Danish biotech drugmaker Genmab's Darzalex, which is used to fight cancer in bone marrow and marketed by Johnson & Johnson, has the potential to achieve annual peak annual sales as high as $13 billion, its chief executive told Reuters.

Feb 22 2017

UPDATE 3-Icahn buys Bristol-Myers shares, adding to activist pressure

Feb 21 Billionaire investor Carl Icahn has taken a stake in Bristol-Myers Squibb Co and sees the drugmaker as a possible takeover target, according to a report published on Tuesday that sent the company's shares from a loss to more than 2 percent higher.

Feb 21 2017

EU mergers and takeovers (Feb 20)

BRUSSELS, Feb 20 The following are mergers under review by the European Commission and a brief guide to the EU merger process:

Feb 20 2017

Kraft Heinz bids $143 billion for Unilever in global brand grab

LONDON U.S. food company Kraft Heinz Co made a surprise $143 billion offer for Unilever Plc in a bid to build a global consumer goods giant, although it was flatly rejected on Friday by the maker of Lipton tea and Dove soap. | Video

Feb 17 2017

How Sanofi lost out to J&J in $30 billion battle for Actelion

ZURICH Swiss biotech company Actelion , days before agreeing to a $30 billion bid by Johnson & Johnson , found a rival offer to be as attractive but went with J&J because its offer provided more certainty, a filing showed on Thursday.

Feb 16 2017

UPDATE 2-How Sanofi lost out to J&J in $30 bln battle for Actelion

* J&J's $280 per share tender offer to start March 3 (Recasts with rival offer, adds background throughout)

Feb 16 2017

BRIEF-Swiss Takeover Commission OKs J&J offer for Actelion

* Swiss Takeover Commission says J&J offer for Actelion meets legal requirements Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

Feb 16 2017

More From Around the Web

Earnings vs. Estimates